Learn more →
Back to Expert Scholars
clinical / clinicalPatient Advocacy & Quality of Care

Véronique Gravis

维罗尼克·格拉维斯

MD, PhD

🏢Institut Paoli-Calmettes, Marseille(马赛保利-卡尔梅特研究所)🌐France

Senior Medical Oncologist; Head, Genitourinary Oncology Unit高级医学肿瘤学家;泌尿肿瘤科主任

36
h-index
3
Key Papers
4
Awards
3
Key Contributions

👥Biography 个人简介

Véronique Gravis is a leading European expert in prostate cancer clinical trials with a particular focus on patient-reported quality of life and the impact of hormone therapy. She coordinates major GETUG group trials and has established France as a center of excellence for patient-centered prostate cancer outcomes research.

Share:

🧪Research Fields 研究领域

Prostate Cancer Patient-Reported Quality of Life前列腺癌患者报告生活质量
Hormone-Sensitive Prostate Cancer激素敏感性前列腺癌
GETUG Clinical TrialsGETUG临床试验
Androgen Deprivation Therapy QoL雄激素剥夺治疗生活质量
Geriatric Oncology老年肿瘤学

🎓Key Contributions 主要贡献

GETUG-AFU 15 Trial & QoL

Led GETUG-AFU 15, the French phase III trial comparing docetaxel plus ADT versus ADT alone in metastatic hormone-sensitive prostate cancer, with QoL as a key endpoint influencing international treatment guidelines.

ADT Quality of Life Assessment

Developed and validated comprehensive QoL assessment frameworks for prostate cancer patients on androgen deprivation therapy, enabling comparison of hormonal treatment regimens by patient-reported impact.

Geriatric Assessment in Prostate Cancer

Integrated geriatric assessment tools into prostate cancer treatment decision-making, improving care individualization for older patients and advocating for age-appropriate quality metrics.

Representative Works 代表性著作

[1]

Androgen-Deprivation Therapy Alone or with Docetaxel in Non-castrate Metastatic Prostate Cancer (GETUG-AFU 15)

The Lancet Oncology (2013)

Pivotal phase III trial of ADT plus docetaxel in mHSPC, including patient-reported QoL endpoints, providing key evidence for combination therapy benefit.

[2]

Health-Related Quality of Life in Patients Receiving Docetaxel Plus Androgen Suppression

European Urology (2015)

Detailed QoL analysis from GETUG-AFU 15, characterizing patient-reported impacts of combination therapy and informing shared decision-making.

[3]

Comprehensive Geriatric Assessment and Therapeutic Decision in Elderly Patients with Prostate Cancer

Annals of Oncology (2020)

Demonstrated that geriatric assessment alters treatment decisions and predicts outcomes in elderly prostate cancer patients, supporting age-tailored care.

🏆Awards & Recognition 奖项与荣誉

🏆GETUG Group Distinguished Research Award
🏆Ligue Nationale Contre le Cancer Research Prize
🏆European Association of Urology Prostate Cancer Research Award
🏆Institut Paoli-Calmettes Research Excellence Award

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 维罗尼克·格拉维斯 的研究动态

Follow Véronique Gravis's research updates

留下邮箱,当我们发布与 Véronique Gravis(Institut Paoli-Calmettes, Marseille)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment